Angela Labrozzi, channel partner director, Within3, outlines how an asynchronous clinical trials model can help pharma and healthcare companies lower emissions, save money, and maximise time.
Bomi Group, a UPS Healthcare company, opened its new storage and distribution facility in Madrid following an 18-million-euro investment. This new logistics centre will be one of the largest warehouses in the European pharmaceutical sector.
Michael Sassano, founder, CEO and chairman of the board, Somai Pharmaceuticals, discusses the European medical cannabis sector, and its impact on pharmaceuticals, alongside the challenges that Somai aims to address.
Simon Tilley, SAS, breaks down the benefits and drawbacks of decentralised clinical trials (DCT). He also explains how AI, machine learning and advanced analytics can refine all stages from participant recruitment to compiling results.
Mayer Schrieber, CEO of Discovery Park, looks at the current situation of Life Sciences and forecasts what steps need to be taken in 2023 to move the sector forward.
Chuck Miller, director of Solution Consulting, AspenTech, gives five important ways technology and automation can support pharma companies with mitigating increased complexity and seizing opportunities in the year ahead.
David Budd, CEO of genedrive says adoption of point of care genetic testing in emergency settings will help save lives and money. However, innovators need to work to persuade healthcare funders to adopt these life-saving technologies.
Dr. Andreas Frerix dives into the challenges Asahi Kasei Bioprocess America (AKBA) faced in using pumping technology for handling inline buffer formulation and single-use virus filtration systems - finding a solution in quaternary diaphragm pumps.
Marcelo Cruz, vice president, Business Development & Marketing at Tjoapack, examines the trends that will impact drug development and the pharma packaging sector in 2023.
EPM conducted a roundtable with several pharma experts to learn what pharma industry trends to watch out for in 2023, from AI drug discovery through to the rise of decentralised trials.
Daniel Samson, head of oligonucleotides at Bachem, gives some insight into the challenges faced when manufacturing on a large scale to meet growing demand.
